[2 cases of odontoma of unusual size].
Explore the source record for details and available documents.
SEARCH · Search PubMed
Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
20 patients with advanced carcinomas of the oral cavity (T3NxMo) were treated at the same time with the cytostatic drugs bleomycin and methotrexate as well as with a cobalt-60-irradiation. 14 of them are tumor free after an observation period of one half to two and a half years. Among them were 4 recurrences that had to be treated surgically. 1 patient is living with a residual tumor which cannot be further treated. 5 patients died of the tumor or of other causes. The survival rate, which is 80% after 1 year, is, as a tentative result, higher than could be attained by other therapeutic measures.
Nine dogs with spontaneous oral fibrosarcomas were given the radiosensitizer misonidazole (Ro-07-0582) In combination with orthovoltage radiotherapy. Although there appeared to be a trend toward greater disease-free survival of these animals as compared with a group of 13 dogs with similar tumors treated by orthovoltage x-rays alone, on analysis there was no significant difference. The plasma half-life and the volume of distribution of misonidazole were determined as 4.95 hours and 15.1 L/m2, respectively. In 3 dogs with evidence of misonidazole toxicosis, plasma concentrations at 4 hours after the dose exceeded 85 microgram/ml, and the areas under the concentration vs time curve for this first 10 hours were greater than 850 microgram.hr/ml.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.